Ex-Hospira chief lands a $91.1M goodbye gift; Diagnostics outfit raises $17.6M;

@FierceBiotech: The 2015 Fierce 15 will be announced in a few weeks. Celebrate the winners with us in October at #BIF15. More | Follow @FierceBiotech

@JohnCFierce: Fibrodysplasia ossificans progressive gets my vote as one of the world's creepiest deadly diseases. Tissue to bone. More | Follow @JohnCFierce

> Pfizer ($PFE) has closed its $15 billion acquisition of Hospira, triggering a $91.1 million golden parachute for outgoing CEO F. Michael Ball. News

> Exosome Diagnostics raised $17.6 million in a second stage of Series B financing, bringing its total round to $44.7 million. The company is working on blood-based tests for lung and prostate cancers. More

> BioTime ($BTX) is plotting to list its shares on Tel Aviv Stock Exchange, tapping "an Israeli market that is becoming a center for biomed and emerging technology companies" while maintaining its NYSE ticker, CEO Michael West said. News

Medical Device News

@FierceMedDev: Focus Diagnostics gets FDA blessing to expand label for herpes test. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: Philips unveils consumer, connected health bid featuring app and 5 devices, including watch. Story | Follow @StacyALawrence

@EmilyWFierce: Report: C.R. Bard downplayed serious problems related to blood-clot device. Article | Follow @EmilyWFierce

> Tornier, Wright merger to close soon after foot and ankle implant divestiture. Report

> Allergan to grab AqueSys for $300M+ to add minimally invasive glaucoma microshunt. Story

> Stryker closing South Carolina surgical equipment manufacturing facility. More

Pharma News

@FiercePharma: Pharma market bets on ASEAN in focus ahead of economic pact. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Last week, Novo announced huge production build-up. This week a warehouse for the raw materials. More from FiercePharmaManutacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Novartis finally gets to roll out inaugural biosim Zarxio. What will payers and docs do? More | Follow @CarlyHFierce

> Undeterred by PTO setbacks, Bass slaps new challenges on Acorda patents. Report

> Ka-Ching: F. Michael Ball cashes out of Hospira with $91.1M. More

> AstraZeneca scores FDA nod for long-term Brilinta use. Story

> Novartis snags EU approval for multiple myeloma med Farydak. Article

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”